Results of a multicentric clinical study of mezlocillin in Japan

Fujii, R.

Arzneimittel-Forschung 29(12a): 2005-2008

1979


ISSN/ISBN: 0004-4172
PMID: 396930
Document Number: 143985
In a clinical trial including 701 patients 6-((R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen) proved effective in the treatment of severe infections. It showed a particularly high efficacy in septicaemia and endocarditis and in purulent meningitis. In cases unresponsive to previous treatment with other antibiotics mezlocillin was effective in about two-thirds of the cases. Side effects were slight and of the same nature as those accompanying other penicillins.

Document emailed within 1 workday
Secure & encrypted payments